Recurrence
Welcome,         Profile    Billing    Logout  
 102 Companies   136 Products   136 Products   123 Mechanisms of Action   5 Trials   1111 News 


12345678910111213...1617»
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) -  Apr 19, 2019   
    P2/3,  N=1108, Completed, 
    Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2019 | Trial primary completion date: Jun 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) -  Mar 7, 2019   
    P2,  N=2000, Completed, 
    Recruiting --> Completed | Trial completion date: Sep 2019 --> Mar 2019 Recruiting --> Completed | N=1500 --> 2000 | Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Phase classification, Trial primary completion date:  Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance (clinicaltrials.gov) -  Jan 28, 2019   
    P=N/A,  N=460, Completed, 
    Recruiting --> Completed | N=1500 --> 2000 | Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019 Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | Trial primary completion date: Aug 2018 --> Nov 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) -  Jan 7, 2019   
    P2,  N=25, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2017 | Trial primary completion date: Nov 2019 --> Sep 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date:  POPCUR: Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease (clinicaltrials.gov) -  Dec 28, 2018   
    P3,  N=61, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2017 | Trial primary completion date: Nov 2019 --> Sep 2017 Recruiting --> Completed | N=122 --> 61 | Trial completion date: Nov 2018 --> Jun 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) -  Nov 19, 2018   
    P2,  N=25, Active, not recruiting, 
    Recruiting --> Completed Trial completion date: Oct 2018 --> Nov 2019 | Trial primary completion date: Oct 2018 --> Nov 2019
  • ||||||||||  esmolol / Generic mfg.
    Trial completion, Trial completion date:  Postoperative Analgesia Impact of Narcotic Free Anesthesia (clinicaltrials.gov) -  Oct 24, 2018   
    P=N/A,  N=84, Completed, 
    Trial completion date: Oct 2018 --> Nov 2019 | Trial primary completion date: Oct 2018 --> Nov 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> May 2018
  • ||||||||||  Arenegyr (NGR-hTNF) / AGC Biologics
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) -  Sep 27, 2018   
    P2,  N=119, Completed, 
    Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: May 2018 --> May 2019 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change:  Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) -  Sep 20, 2018   
    P3,  N=30, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016 N=43 --> 30
  • ||||||||||  docetaxel / Generic mfg.
    Enrollment change, Trial termination, Combination therapy, Surgery, Metastases:  Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Jul 24, 2018   
    P2,  N=42, Terminated, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> May 2017 N=100 --> 42 | Recruiting --> Terminated; The trial was stopped for futility in view of the results of the anticipated analysis
  • ||||||||||  gemcitabine / Generic mfg.
    Trial completion, Enrollment change:  Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  May 2, 2018   
    P2/3,  N=58, Completed, 
    Recruiting --> Completed | N=20 --> 90 | Trial completion date: Oct 2015 --> Mar 2018 Active, not recruiting --> Completed | N=116 --> 58
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) -  Apr 13, 2018   
    P2/3,  N=1061, Active, not recruiting, 
    Active, not recruiting --> Completed | N=116 --> 58 Recruiting --> Active, not recruiting | N=200 --> 1061 | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Jun 2018
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial termination, Trial primary completion date:  Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients (clinicaltrials.gov) -  Mar 30, 2018   
    P=N/A,  N=120, Terminated, 
    Recruiting --> Active, not recruiting | N=200 --> 1061 | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Jun 2018 Trial completion date: Sep 2020 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; The PI left the Institution.
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Biomarker, New P2 trial:  Neoadjuvant Pazopanib in Renal Cell Carcinoma (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=21, Completed, 
  • ||||||||||  Enrollment open, Trial primary completion date:  Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors (clinicaltrials.gov) -  Dec 11, 2017   
    P=N/A,  N=320, Recruiting, 
    Trial primary completion date: Mar 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Dec 2020
  • ||||||||||  Trial completion, Trial initiation date, Trial primary completion date:  DETECT: The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease (clinicaltrials.gov) -  Dec 7, 2017   
    P4,  N=142, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Dec 2020 Recruiting --> Completed | Initiation date: Dec 2013 --> Feb 2013 | Trial primary completion date: Jun 2016 --> Dec 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Should Prosthetic Repair of Incisional Abdominal Hernias be Drain or Not? (clinicaltrials.gov) -  Nov 18, 2017   
    P=N/A,  N=200, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=380 --> 200 | Trial primary completion date: Dec 2015 --> Oct 2017
  • ||||||||||  docetaxel / Generic mfg.
    Trial primary completion date, Combination therapy, Surgery, Metastases:  Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Nov 18, 2017   
    P2,  N=100, Recruiting, 
    Recruiting --> Completed | N=380 --> 200 | Trial primary completion date: Dec 2015 --> Oct 2017 Trial primary completion date: Jan 2017 --> Oct 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV (clinicaltrials.gov) -  Nov 17, 2017   
    P4,  N=1050, Completed, 
    Trial primary completion date: Jan 2017 --> Oct 2017 Recruiting --> Completed | N=2018 --> 1050 | Trial primary completion date: Dec 2016 --> May 2017
  • ||||||||||  Trial primary completion date:  FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) -  Nov 6, 2017   
    P2,  N=25, Active, not recruiting, 
    Recruiting --> Completed | N=2018 --> 1050 | Trial primary completion date: Dec 2016 --> May 2017 Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  tasadenoturev (DNX-2401) / DNAtrix
    Trial completion, Oncolytic virus:  D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) -  Oct 24, 2017   
    P1,  N=31, Completed, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Active, not recruiting --> Completed
  • ||||||||||  imatinib / Generic mfg.
    Trial completion, Trial primary completion date, Stroma:  Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) -  Aug 28, 2017   
    P2,  N=91, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial termination:  Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) -  Aug 22, 2017   
    P3,  N=43, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Aug 2016; Lack of recruitment Completed --> Terminated; Voluntarily terminated by PI due to lack of feasibility.